Abstract
The use of antiandrogen drugs such as finasteride during pregnancy may carry the risk of birth defects, especially hypospadias. We report a 39-year-old woman, with 5 weeks unplanned pregnancy, the patient conceived while receiving daily dose of finasteride 2.5 mg for treatment of alopecia. The patient’s partner was concurrently using finasteride for the same purpose. Ultrasound scans including detailed anatomy were normal throughout pregnancy and the fetal gender was detected to be male. The patient had her delivery at 38+5 weeks’ gestation, by elective cesarean section, a male infant with a weight of 3.58 kg and Apgar score of 9 and 10 at 1 and 5-min, respectively. The infant was healthy with no obvious dysmorphic features. In this case report, maternal use of finasteride in early pregnancy was not associated with external genitalia abnormalities of a male baby. Moreover, maternal exposure to the semen of partner who received finasteride did not adversely affect the short term neonatal outcomes. However, absence of apparent neonatal adverse effects in a single case report does not indicate safety of use. Population-based long term neonatal outcomes are yet to be established.
This is a preview of subscription content, log in via an institution to check access.
References
Finasteride. Food and Drug Administration (FDA). Jan 2014. Available at: http://www.fda.gov/. Accessed 6th Dec 2017.
Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 2013;11(4):e9860.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56–62.
Clark RL, Antonello JM, Grossman SJ, Wise LD, Anderson C, Bagdon WJ, et al. External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alpha-reductase inhibitor. Teratology. 1990;42(1):91–100.
Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74:393–406.
Prahalada S, Tarantal AF, Harris GS, Ellsworth KP, Clarke AP, Skiles GL, et al. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology. 1997;55(2):119–31.
Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy? Can Fam Physician. 2001;47:2469–70.
Laborde E, Brannigan E. Effect of 1-mg Dose of Finasteride on Spermatogenesis and Pregnancy. J Androl. 2010;31:e1–2.
Ahn KH, Shin J, Hong SC, Han JY, Lee EH, Lee JS, et al. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case series. J Clin Toxicol. 2015;5(2):248.
Overview of off-label use of 5-apha reductase inhibitors in women. Netherland pharmacovigilance center lareb. Apr 2015. Available at: http://www.lareb.nl/?lang=en-GB. Accessed 6th Dec 2017.
Sallout BI, Al Wadi KA. Aphalangia possibly linked to unintended use of finasteride during early pregnancy. Ann Saudi Med. 2009;29(2):155.
Funding
No funding was received for the current work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Authors declare no conflict with interest.
Rights and permissions
About this article
Cite this article
AlSaad, D., Lee, B.H. & Al-Obaidly, S. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm 40, 803–805 (2018). https://doi.org/10.1007/s11096-018-0661-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-018-0661-5